For nearly two years after learning of non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) impacting its hemodialysis machines, Fresenius Medical Care failed to take appropriate action, according to a December warning letter from the Food and Drug Administration.
In its letter, the FDA listed several violations stemming from an investigation last summer of the company’s Massachusetts facility where...






